Related Experiment Video

Updated: May 28, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Treatment of symptomatic coronary artery disease with stent implantation

Tita Butenko1, Darja Dobovšek, Luka Lipar

  • 1Department of Cardiology, University Medical Centre of Ljubljana, Slovenia.

Lijecnicki Vjesnik
|November 4, 2011
PubMed

Insights

Drug-eluting stents (DES) are more effective than bare metal stents (BMS) in preventing major adverse cardiac events (MACE) after coronary interventions. Longer lesions treated with BMS may result in higher residual stenosis, impacting outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Percutaneous coronary intervention (PCI) with stent implantation is a primary treatment for coronary artery disease.
  • Bare metal stents (BMS) and drug-eluting stents (DES) are commonly used stent types.

Purpose of the Study:

  • To evaluate the efficacy of BMS in symptomatic coronary artery disease.
  • To compare BMS with DES in preventing major adverse cardiac events (MACE) six months post-implantation.

Main Methods:

  • Retrospective analysis of 387 patients with BMS and 74 patients with DES.
  • Efficacy assessed by residual in-stent stenosis.
  • MACE defined as cardiac death, acute myocardial infarction (AMI), or target vessel revascularization.

Main Results:

  • DES implantation showed significantly lower MACE incidence within six months compared to BMS.
  • Longer lesions treated with BMS were associated with higher residual in-stent stenosis.
  • Hypertension was the most common risk factor; AMI was the primary indication for BMS, while angina was for DES.

Conclusions:

  • BMS is an effective treatment for symptomatic coronary artery disease.
  • DES implantation is superior to BMS in preventing MACE.
  • Longer lesions pose a challenge for BMS, leading to higher residual stenosis.
Abstract

More Related Videos

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access05:04

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access

Published on: November 19, 2020

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...